– UK, Nottingham – Source BioScience plc (LSE: SBS) the international laboratory services and products business, announces that Tim Jackson-Smith will join the Board as a Non-Executive Director with immediate effect.
Tim is an experienced corporate and commercial lawyer with 20 years’ experience in legal practice, including ten years as a Partner. In addition, Tim has significant, relevant experience in the plc environment, having served for more than eight years in both executive and non-executive director roles at a number of main market and AIM listed companies.
The Company also announces that Dr Sue Foden, Senior Independent Director, will be stepping down from the Board at the conclusion of her current term of appointment on 31 August 2015.
Laurie Turnbull, Chairman, said: “I would like to thank Sue, on behalf of the Board and everyone at Source BioScience, for her tremendous contribution over the past twelve years.
“Sue’s breadth of knowledge and understanding of the scientific and medical research industries has been of invaluable assistance during her tenure, along with her commitment, common-sense approach and utmost integrity. We wish her well with her continuing corporate and private interests.
“I am delighted to welcome Tim to the Board. Tim has significant experience in senior leadership roles, across a broad spectrum of organisations and will bring knowledge and an important, additional skill base to the Board as we continue with the implementation of the Group’s growth strategy.”
About Source BioScience
Source BioScience plc (LSE: SBS) is a trusted provider of state of the art laboratory services and products to the healthcare and clinical, life and applied sciences and biopharma industries. It is an international business operating ten state of the art facilities in five countries and with customers in over 90 countries worldwide. The Group offers a complementary portfolio of laboratory services and products that share common technologies, laboratory processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These services and products are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.